Creative Biolabs has launched a new platform leveraging phage display, B cell technologies, and hybridoma screening to accelerate the development of non-IgG antibodies like IgA, IgM, and IgE. Their tailored services address challenges in expression, purification, humanization, and glycoengineering, ensuring high-quality antibody candidates through comprehensive characterization methods. By emphasizing collaboration and innovation, Creative Biolabs aims to drive progress in the field of antibody therapeutics.
